{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:20:59Z","timestamp":1792804859141,"version":"4.5.0"},"reference-count":38,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Korea Health Industry Development Institute","id":[{"id":"https:\/\/ror.org\/00fdzyk40","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Ministry of Health & Welfare, Republic of Korea","award":["RS-2025-02263271"],"award-info":[{"award-number":["RS-2025-02263271"]}],"id":[{"id":"https:\/\/ror.org\/00vxgjw72","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Soonchunhyang University Research Fund","id":[{"id":"https:\/\/ror.org\/03qjsrb10","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Renin\u2013angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), have been associated with improved outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to assess the differential impact of ACEIs versus ARBs on survival and cardiovascular outcomes in individuals with MASLD. Using data from the UK Biobank, we identified 52,143 participants with exclusive use of either an ACEI or ARB. Individuals with viral, autoimmune, cholestatic, or alcohol-related liver disease were excluded. MASLD was defined as fatty liver index \u2265 60 with \u22651 cardiometabolic risk factor. Inverse probability of treatment weighting (IPTW) was used to adjust for confounders. Outcomes included all-cause mortality, cardiovascular events, hepatic decompensation, and hepatocellular carcinoma (HCC), analyzed using Cox proportional hazards models. Among MASLD participants, ARB use was associated with significantly lower all-cause mortality compared to ACEI use (HR, 0.94; 95% CI, 0.90\u20131.00; p = 0.031) after IPTW adjustment. Cardiovascular risk was also lower with ARBs (HR, 0.92; 95% CI, 0.89\u20130.96; p &lt; 0.001), particularly in subgroups with BMI \u2265 25 kg\/m2, no diabetes, and advanced fibrosis. No differences in hepatic decompensation or HCC incidence were observed. Benefits of ARBs were not significant in participants without steatotic liver disease. ARB use was associated with improved survival and reduced cardiovascular events in individuals with MASLD, whereas ACEIs expressed no comparable benefit. These findings suggest that ARBs might be a more effective RAS inhibitor subclass in MASLD and support their preferential use in patients with steatotic liver disease requiring antihypertensive therapy.<\/jats:p>","DOI":"10.3390\/ijms262010061","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:17:02Z","timestamp":1760617022000},"page":"10061","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD"],"prefix":"10.3390","volume":"26","author":[{"given":"Tom","family":"Ryu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, College of Medicine, Soonchunhyang University, Seoul 04401, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Joo","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-9350","authenticated-orcid":false,"given":"Jaejun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-1450","authenticated-orcid":false,"given":"Ji Won","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-9806","authenticated-orcid":false,"given":"Hyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keungmo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3350\/cmh.2024.0987","article-title":"Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017\u20132023","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Mol Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstrom","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Radosavljevic, T., Brankovic, M., Samardzic, J., Djuretic, J., Vukicevic, D., Vucevic, D., and Jakovljevic, V. (2024). Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches. Antioxidants, 13.","DOI":"10.3390\/antiox13080906"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/hepr.14008","article-title":"Advancements in metabolic-associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions","volume":"54","author":"Eeda","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41440-018-0040-6","article-title":"The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: A brief review","volume":"41","author":"Borem","year":"2018","journal-title":"Hypertens. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kim, K.M., Roh, J.H., Lee, S., and Yoon, J.H. (2021). Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-81959-1"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"McGrath, M.S., and Wentworth, B.J. (2024). The Renin-Angiotensin System in Liver Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115807"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3748\/wjg.15.2579","article-title":"Renin-angiotensin system in the pathogenesis of liver fibrosis","volume":"15","author":"Pereira","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/ars.2016.6669","article-title":"MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome\/IL-1beta Axis via Targeting Smad7 and Spry1","volume":"27","author":"Ning","year":"2017","journal-title":"Antioxid. Redox Signal"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/hep.21638","article-title":"Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis","volume":"45","author":"Hirose","year":"2007","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/hep4.1104","article-title":"Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis","volume":"1","author":"Namisaki","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cgh.2023.07.009","article-title":"Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis","volume":"22","author":"Elhence","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ng, W.H., Yeo, Y.H., Kim, H., Seki, E., Rees, J., Ma, K.S., Moylan, C.A., Rodriquez, L.M., Abdelmalek, M., and Villanueva, A. (2025). Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data. Hepatology.","DOI":"10.1097\/HEP.0000000000001333"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/hr.2017.65","article-title":"Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: How to achieve better end-organ protection?","volume":"40","author":"Nehme","year":"2017","journal-title":"Hypertens. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1751-7176.2010.00379.x","article-title":"Pleiotropic effects of angiotensin receptor blockers: Addressing comorbidities by optimizing hypertension therapy","volume":"13","author":"Toth","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/hc3001.094733","article-title":"Manipulation of the renin-angiotensin system","volume":"104","author":"Givertz","year":"2001","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/hr.2009.5","article-title":"Inhibition of the renin-angiotensin system and target organ protection","volume":"32","author":"Iwanami","year":"2009","journal-title":"Hypertens. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/jcbfm.2013.219","article-title":"Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow","volume":"34","author":"Sigurdsson","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10571-009-9368-4","article-title":"Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery","volume":"29","author":"Benicky","year":"2009","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kim, H., Baek, C.H., Lee, R.B., Chang, J.W., Yang, W.S., and Lee, S.K. (2017). Anti-Fibrotic Effect of Losartan, an Angiotensin II Receptor Blocker, Is Mediated through Inhibition of ER Stress via Up-Regulation of SIRT1, Followed by Induction of HO-1 and Thioredoxin. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020305"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/HYPERTENSIONAHA.109.140145","article-title":"Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases","volume":"55","author":"Ferreira","year":"2010","journal-title":"Hypertension"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00535-008-2239-9","article-title":"Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model","volume":"43","author":"Kim","year":"2008","journal-title":"J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bramel, E.E., Bagirzadeh, R., Saqib, M., Creamer, T.J., Espinoza Camejo, W.A., Roker, L.A., Pardo Habashi, J., Dietz, H.C., and Gallo MacFarlane, E. (2022). Distinct Contribution of Global and Regional Angiotensin II Type 1a Receptor Inactivation to Amelioration of Aortopathy in Tgfbr1 (M318R\/+) Mice. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.936142"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/ATVBAHA.117.309863","article-title":"Deletion of NF-kappaB\/RelA in Angiotensin II-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation","volume":"37","author":"Ijaz","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-019-0847-8","article-title":"The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat","volume":"18","author":"Habibi","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tanaka, M., Kaji, K., Nishimura, N., Asada, S., Koizumi, A., Matsuda, T., Yorioka, N., Tsuji, Y., Fujinaga, Y., and Sato, S. (2024). Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis. Biochim. Biophys. Acta Mol. Cell Res., 1871.","DOI":"10.1016\/j.bbamcr.2023.119649"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mathey, C.M., Maj, C., Scheer, A.B., Fazaal, J., Wedi, B., Wieczorek, D., Amann, P.M., L\u00f6ffler, H., Koch, L., and Sch\u00f6ffl, C. (2022). Molecular Genetic Screening in Patients With ACE Inhibitor\/Angiotensin Receptor Blocker-Induced Angioedema to Explore the Role of Hereditary Angioedema Genes. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.914376"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.hrthm.2009.06.013","article-title":"Genetic variation in angiotensin-converting enzyme-related pathways associated with sudden cardiac arrest risk","volume":"6","author":"Sotoodehnia","year":"2009","journal-title":"Heart Rhythm"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2410416","DOI":"10.1002\/advs.202410416","article-title":"Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies","volume":"12","author":"Di","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., and Landray, M. (2015). UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001779"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., and Tiribelli, C. (2006). The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Mallet","year":"2007","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10061\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:20:17Z","timestamp":1760617217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":38,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms262010061"],"URL":"https:\/\/doi.org\/10.3390\/ijms262010061","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}